Health & Biotech
Struggling coal mining town Collie is WA govt’s choice for new hemp processing plant
Is biotech Dimerix the next billion-dollar Opthea?
Check up: Health stocks firing on excitement… and little else
Weed Week: Domestic cannabis players set to benefit from new export laws
MGC Pharma strikes Russian COVID supply deal, as corona cases soar in the region
Health: PharmAust proves its doggie cancer drug works; shares up 40pc
Hand sanitiser king says Zoono isn’t betting on your hand cleaning habits
Dr Boreham’s Crucible: A simpler device gives Atomo the upper hand in blood-based diagnostics
HeraMED ramps up Australian strategy with new distribution deal
ATO blocks biotech access to Jobkeeper wage subsidy
Health Kick Podcast: Can listed Aussie drug makers survive COVID-19?
Scale-up secret sauce: These are the ingredients for medtech growth
Here’s why biotech Dimerix is on a golden run
Shareholders back Respiri’s new story with strong support for capital raise
NZ’s pot reform bill is here: edibles are in, drinks are out
Bondi backpackers rejoice! Recce may have a gonorrhoea cure
Stockhead V-Con: The Future of TeleHealth — everything you need to know about Stockhead’s inaugural video conference
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.
